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Abstract
Background: In addition to increased cardiovascular risk, patients with primary 
aldosteronism (PA) also suffer from impaired health-related quality of life (HRQoL) and 
psychological symptoms. We assessed for changes in HRQoL and depressive symptoms 
in a cohort of Asian patients with PA, after surgical and medical therapy.
Methods: Thirty-four patients with PA were prospectively recruited and completed 
questionnaires from 2017 to 2020. HRQoL was assessed using RAND-36 and EQ-5D-3L, 
and depressive symptoms were assessed using Beck Depression Inventory (BDI-II) at 
baseline, 6 months, and 1 year post-treatment.
Results: At 1 year post-treatment, significant improvement was observed in both physical 
and mental summative scores of RAND-36, +3.65, P = 0.023, and +3.41,  
P = 0.033, respectively, as well as four subscale domains (physical functioning, bodily 
pain, role emotional, and mental health). Significant improvement was also seen in 
EQ-5D dimension of anxiety/depression at 1 year post-treatment. Patients treated with 
surgery (n = 21) had significant improvement in EQ-5D index score post-treatment and 
better EQ-5D outcomes compared to the medical group (n = 13) at 1 year post-treatment. 
37.9, 41.6 and 58.6% of patients had symptoms in the cognitive, affective and somatic 
domains of BDI-II, respectively. There was a significant improvement in the affective 
domain of BDI-II at 1 year post-treatment.
Conclusion: Both surgical and medical therapy improve HRQoL and psychological 
symptoms in patients with PA, with surgery providing better outcomes. This highlights the 
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Hypertension is the largest single contributor to the global 
burden of disease and mortality (1), and 5–20% of all patients 
are estimated to suffer from primary aldosteronism (PA). 
Compared to patients with essential hypertension, patients 
with PA have an increased risk of cardiovascular disease 
and renal failure (2, 3). In addition, several studies have 
shown that patients with PA have a poorer health-related 
quality of life (HRQoL) and may also suffer from anxiety 
and depression (4, 5). Generally, bilateral PA is treated 
with mineralocorticoid receptor (MR) antagonists, while 
unilateral PA is managed with unilateral adrenalectomy (6). 
Studies have found better cardiovascular events and HRQoL 
outcomes following surgical treatment (2, 5). Adrenal vein 
sampling (AVS) is required to differentiate unilateral from 
bilateral PA and is technically challenging to perform (7). 
If surgery leads to better outcomes than medical treatment, 
then it will be ideal for all patients to undergo subtype 
testing and will be offered the appropriate treatment (6).
There has been increasing attention in recent years 
towards not just physician-identified issues but patient-
reported outcome measures (PROM). Hence, PROMs have 
been developed to assess general HRQoL (8). PROMs cover 
multiple domains of health that are influenced by patient’s 
subjective experiences, perceptions, and beliefs (9). These 
include pain, physical functioning, mobility, mood and 
other important areas of functioning. To date, few studies 
have examined HRQoL outcomes in PA cohorts (5, 10, 11), 
and none have been conducted in an Asian cohort. Previous 
studies have shown that HRQoL appears to be lower in 
patients with PA compared to the general population 
(5, 10, 11). While there is improvement after treatment, 
patients who have undergone adrenalectomy appear to 
respond better than those on long-term medications. In 
addition, other studies have shown that patients with 
PA have significant psychological symptoms, which may 
improve after treatment (5).
Hence, in this prospective observational study, we 
aimed to assess for both HRQoL and depressive symptoms 
in a cohort of patients with PA after appropriate treatment 
with either surgical or medical therapy based on the 
underlying subtype of PA. Our secondary aim was to 
compare the effects of surgical and medical therapy.
Materials and methods
Study design and patients
We performed a prospective, observational clinical study to 
assess for improvement in patient outcomes after treatment 
of PA. The PA PACES study (prospective study assessing 
blood pressure, cardiovascular, endothelial and other 
outcomes post-surgical and medical treatment in patients 
with PA) was conducted in a tertiary centre, Changi General 
Hospital, from January 2017 to September 2020. The study 
was registered with clinicaltrials.gov (NCT03174847), 
approved by SingHealth Centralised Institutional Review 
Board (CIRB Reference number 2016/2888), and informed 
consent was obtained from all participants.
We included patients of age 18 years or older, with a 
confirmed diagnosis of PA in accordance with the 2016 
Endocrine Society Guidelines (6). For the purpose of 
assessing HRQoL, patients were required to be English-
literate. From July 2017, Chinese-literate patients were 
included and they completed European Quality of Life-5 
Dimensions (EQ-5D-3L) (Chinese version). Exclusion 
criteria were patients with adrenal carcinoma, severe 
or terminal co-morbidity that interfered with possible 
treatment or HRQoL, or glucocorticoid-remediable 
aldosteronism. Prior to hormonal tests, antihypertensive 
medications which interfered with renin and aldosterone 
levels (e.g. ACE-inhibitors, diuretics) were discontinued 
for at least 2 weeks in most patients, while potassium-
sparing diuretics were discontinued for at least 6 weeks 
in all patients. Hypokalaemia, if present, was corrected 
with potassium supplementation, aiming for serum 
potassium ≥ 3.5 mmol/L before hormone measurements. 
Plasma aldosterone concentration (PAC) and plasma 
renin activity (PRA) were determined in all patients as 
previously reported (12). Patients underwent i.v. seated 
saline infusion test and all patients had a post-saline 
infusion PAC ≥ 140 pmol/L (6). Patients underwent a 
thin-slice CT imaging of the adrenal glands. Unilateral 
adenoma was defined as a unilateral adrenal nodule of at 
least 8 mm, while the contralateral gland was normal and 
not enlarged. Patients seeking a surgical cure underwent 
adrenal vein sampling (AVS) to determine lateralisation. 
AVS was performed under continuous corticotropin, 
with sequential cannulation of the right adrenal vein, 
left adrenal vein, and infra-renal inferior vena cava 
(IVC). Selectivity index was calculated by the adrenal 
vein cortisol to IVC cortisol ratio, and a gradient of at 
least three was taken to be successful. Lateralisation ratio 
was calculated by the higher adrenal vein aldosterone-
to-cortisol ratio divided by the contralateral side. 
Lateralisation ratio greater than four was consistent with 
unilateral PA and a ratio below three consistent with 
bilateral PA. Patients with lateralisation ratios between 
three and four were discussed at a multi-disciplinary 
meeting to decide on subtype and treatment modality. 
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All patients treated with surgery underwent unilateral 
adrenalectomy via a minimally invasive transabdominal 
laparoscopic approach.
Assessment of HRQoL and psychological symptoms
HRQoL was assessed at baseline before treatment, 
6 months, and 1 year post-treatment using two validated 
questionnaires: RAND 36-Item Health Survey (13) and 
the EQ-5D-3L (14) instrument. Depressive symptoms were 
assessed with the Beck Depression Inventory-II (BDI-II) 
(15). RAND-36 comprises 36 questions evaluating eight 
domains: physical functioning (PF), role limitations due to 
physical problems (RP), role limitations due to emotional 
problems (RE), vitality (VT), mental health (MH), social 
functioning (SF), bodily pain (BP), and general health 
perception (GH). The physical component summary (PCS) 
and mental component summary (MCS) are summations 
of the eight weighted subscale domains, and a national 
normative scoring is utilised where 50 indicates the 
adjusted mean and 10 is the standard deviation (s.d.) of 
the general population in Singapore (16, 17). A higher score 
represents a higher HRQoL. Question 2 addresses perceived 
health change (HC) compared to general health 1 year ago 
and is reported separately (range 0 to 100).
EQ-5D-3L comprises five questions relating to five 
dimensions of mobility, self-care, usual activity, pain/
discomfort, and anxiety/depression (14). Within each 
dimension, responses are divided into 'no problems', 
'some or moderate problems' or 'extreme problems', and 
the scores are tabulated using weighted item score into 
a summary index (EQ-5D index score) according to the 
general populations norms in Singapore (18). The index 
score is represented by the utility or 1 – disutility. A factor 
loading score is subtracted from an original utility of 1 
for any dimension faring worse than 'no problems'. An 
additional factor score is subtracted if the patient reports 
'extreme problems' for any of the dimensions. This would 
result in a final score between the range of −0.7694 to 1, 
where 1 is the best possible outcome (18). A visual analogue 
scale (EQ-VAS) allows patients to rate their current health 
status on a range from 0 to 100, and a higher score represents 
better health status. Since most patients reported 'no 
problems', we performed binary grouping, with patients 
reporting 'no problems' separated from those patients 
with moderate or extreme problems.
BDI-II comprises 21 questions relating to various aspects 
of depressive symptoms, which can be broadly grouped 
into cognitive, affective, and somatic symptoms (15). 
Within each domain, responses are divided into four 
choices, which will be converted into score of 0, 1, 2, or 3, 
and the scores are computed into a tallied score between 
the range of 0–63 (BDI score). A higher score represents 
more depressive symptoms. We have categorised the results 
into 0–13 (minimal depressive symptoms) vs 14–63 (mild 
to severe depressive symptoms) (15). We used the 3-factors 
model proposed by Buckley et  al. where each of the 21 
questions is separated into three different factors using 
the factor loading score of how each question is specific 
to a certain domain (19, 20). A higher score denotes more 
severe symptoms in the particular domain (19). Additional 
analysis was done to compare patients who reported a 
score of 0 (no complaint) vs >0 (some degree of complaint) 
for each question.
Statistical analysis
Statistical analysis was performed using SPSS version 26.0 
(IBM Corp.). Continuous variables were expressed as mean 
(s.d.) or median (IQR), and compared using independent 
t-test or Mann–Whitney U-test as appropriate. Chi-square 
test was used for categorical variables. Statistical significance 
was set at P value less than 0.05. For the analysis of the 
treatment outcome on RAND-36 subscales and summary 
scores, EQ-5D VAS, and BDI score after 6 months and 
1 year, paired t-test was used to compare with baseline. For 
comparison with the general population, an independent 
t-test was used for RAND-36 subscales, RAND-36 summary 
score, and EQ-VAS (17). For comparison of EQ-5D index 
score and RAND-36 health changes compared to 1 year 
ago, Wilcoxon signed-rank test was used (18). Patients were 
included if they had filled up a baseline questionnaire.
Results
Eighty-six patients underwent a saline infusion test, 61 
patients were confirmed with PA (Fig. 1), and 4 patients 
declined to participate. Fifty-seven patients were recruited 
into the main study with 23 excluded as they did not 
complete the baseline questionnaires. All patients included 
in the study who underwent saline infusion had post-saline 
PAC ≥ 162 pmol/L, (21, 22) except for one patient (with 
PAC 140 pmol/L). The remaining 34 were included in this 
study for assessing HRQoL and psychological symptoms, 
of which mean age is 51.3 years and 29.4% were females. 
Twenty-one patients were treated with surgery while 13 
were treated with medications (Table 1). Thirty-three 
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patients underwent AVS with all having successful bilateral 
cannulation. Twenty-five patients had lateralisation on 
AVS, with 21 undergoing unilateral adrenalectomy. The 
remaining four patients did not proceed with surgery: two 
patients had borderline lateralisation ratio (both 4.1), one 
patient changed her mind, one patient delayed surgery for 
personal reasons and is on interim medical therapy.
Twenty-nine patients filled out EQ-5D (English), and 
five patients filled out EQ-5D (Chinese) version. 76.5% of 
the patients were Chinese, 11.8% Malays, 5.9% Indians, 
and 5.9% others, which is similar to the population 
demographics. Patients treated with surgery were younger 
and had lowest-ever recorded serum potassium. There were 
otherwise no significant differences between the groups. 
Patients who completed questionnaires were younger, 
had higher eGFR and lower prevalence of hyperlipidemia, 
compared to those without questionnaires filled as shown 
in Supplementary Table 1 (see section on supplementary 
materials given at the end of this article). The remaining 
baseline characteristics between the groups were 
otherwise similar.
Baseline
At baseline, there were no significant differences between 
the two treatment groups in all eight RAND-36 domains, 
PCS, MCS, EQ-5D index or EQ-5D VAS (Table 1). At 
baseline, when compared to the reference population, 
there was no significant difference in baseline RAND-36 or 
EQ-5D observed in our study cohort.
RAND-36
At 6 months, while there was an improvement in all the 
variables, none of them reached statistical significance. 
At 1 year, there were significant improvements in 
four domains of physical functioning (+7.02 (95% CI: 
0.312–13.72)), bodily pain (+7.41 (95% CI: 0.284–14.53)), 
role emotional (+11.11 (95% CI: 0.767–21.46)), mental 
health (+5.85 (95% CI: 2.00–9.71)), as well as both 
summative scores PCS (+3.65 (95% CI: 0.555–6.75)) and 
MCS (+3.41 (95% CI: 0.291–6.52)) (Fig. 2). In addition, 
there was an improvement in perceived health changes 
Figure 1
Consort diagram of patients included in the study 
with questionnaires.
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from baseline. Stratified by treatment groups, significant 
improvements in mental health, P = 0.033, and PCS, 
P = 0.048, were seen in the surgical group, but none of the 
variables reached statistical significance in the medical 
group (Table 2). At 1 year, mean values of all the domains 
were lower in the medical compared to the surgical group, 
although none were statistically significant. Stratified by 
gender, significant improvements were seen for females 
in the MCS subscale, as well as four domains (physical 
functioning, bodily pain, general health and mental 
health), whereas this was not seen in male patients as seen 
in Supplementary Table 2.
EQ-5D
In the entire cohort, improvements in five dimensions and 
the EQ-5D index score were not statistically significant when 
compared to baseline post-treatment (Table 3). Similarly, the 
VAS score changed from 80.6 (12.9) at baseline to 82.6 (9.0) 
at 1 year post-treatment, P = 0.14. However, when stratified 
by treatment, there was a significant improvement in EQ-5D 
index score in the surgical group post-treatment, from 1.00 
(IQR 0.85–1.00) to 1.00 (IQR 1.00–1.00), P = 0.034, but this 
was not significant in the medical group. In addition, at 1 
year post-treatment, there were more patients in the surgical 
Table 1 Baseline characteristics of 34 patients with primary aldosteronism who has completed baseline questionnaire.
Total (n = 34) Surgical (n = 21) Medical (n = 13) P
Age (years) 51.3 (11.4) 48.1 (11.4) 56.4 (9.6) 0.036
Gender, females (%) 10 (29.4%) 8 (38.1%) 2 (15.4%) 0.16
Ethnicity (%) 0.12
 Chinese 26 (76.5%) 16 (76.2%) 10 (76.9%)
 Malay 4 (11.8%) 4 (19.0%) 0 (0%)
 Indian 2 (5.9%) 0 (0%) 2 (15.4%)
 Others 2 (5.9%) 1 (4.8%) 1 (7.7%)
BMI (kg/m2) 27.5 (5.4) 26.9 (5.3) 28.6 (5.6) 0.37
Systolic blood pressure 149.1 (16.9) 148.1 (16.7) 150.7 (17.8) 0.68
Diastolic blood pressure 86.0 (8.9) 86.0 (10.1) 85.9 (7.0) 0.98
BP Meds, DDD 3.1 (2.2) 3.2 (1.9) 3.0 (2.7) 0.78
Lowest K 2.7 (0.5) 2.4 (0.4) 3.1 (0.4) <0.001
eGFR 88.6 (18.8) 88.45 (20.3) 88.8 (16.9) 0.96
Years of hypertension (n = 27) 9.0 (0–24.0) 8.0 (0–23.0) 20.0 (3.0–37.0) 0.21
Ischeamic heart dsease (%) 3 (8.8%) 1 (4.8%) 2 (15.4%) 0.29
CKD (%) 2 (5.9%) 2 (9.5%) 0 (0%) 0.25
Cerebrovascular accident (%) 3 (8.8%) 3 (14.3%) 0 (0%) 0.15
Hyperlipidaemia (%) 13 (38.2%) 7 (33.3%) 6 (46.2%) 0.46
Diabetes mellitus (%) 12 (35.3%) 7 (33.3%) 5 (38.5%) 0.76
CT scan results (%) 0.40
 Unilateral adenoma 23 (67.6%) 16 (76.2%) 7 (53.8%)
 Bilateral abnormalities 2 (5.9%) 1 (4.8%) 1 (7.7%)
 Bilateral normal 9 (26.5%) 4 (19.0%) 5 (38.5%)
EQ-5D index score 1.00 (0.850–1.00) 1.00 (0.850–1.00) 1.00 (0.850–1.00) 0.89
EQ-5D VAS (n = 31) 80.6 (12.9) 82.1 (11.4) 78.5 (14.9) 0.46
BDI score (n = 28) 6.2 (8.3) 6.0 (8.9) 6.6 (7.9) 0.87
RAND-36 (n = 29)
Subscales
 Physical functioning 82.9 (18.5) 83.3 (18.7) 82.3 (19.2) 0.88
 Role physical 77.6 (36.2) 79.2 (32.4) 75.0 (43.3) 0.77
 Bodily pain 83.5 (21.6) 86.3 (18.7) 79.1 (25.9) 0.40
 General health 67.1 (17.9) 68.1 (18.5) 65.5 (17.7) 0.71
 Vitality 71.2 (18.6) 72.2 (16.8) 69.6 (22.0) 0.71
 Social functioning 82.3 (25.6) 86.1 (19.1) 76.1 (33.8) 0.32
 Role emotional 83.9 (32.9) 81.5 (34.7) 87.9 (30.8) 0.62
 Mental health 79.1 (17.8) 79.8 (17.9) 78.0 (18.5) 0.80
PCS 50.8 (8.2) 51.0 (7.9) 50.4 (9.1) 0.87
MCS 52.7 (11.3) 53.8 (10.6) 51.1 (12.6) 0.54
Health changes 50.0 (25.0–75.0) 50.0 (19.0–81.0) 50.0 (50.0–50.0) 0.81
Values are presented in mean (s.d.), median (interquartile range) or number (percentage).
BP Meds, blood pressure medications; CKD, chronic kidney disease; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; K, potassium; 
MCS, mental component summary; PCS, physical component summary; VAS, visual analogue score.
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group who had no issues overall compared to the medical 
group, 90% vs 58.3%, P = 0.036. In male patients, 12 of 12 
(100%) had no issues 1 year post-adrenalectomy, compared 
to 5 of 10 (50%) post-medical therapy, P = 0.005 seen in 
Supplementary Table 3. Differences between treatment 
methods were not evident for females patients. At 1 year 
post-treatment, females had a better VAS score of 88.5 (7.1) 
compared to males 79.9 (8.6), P = 0.010.
BDI-II
The overall BDI score was 6.2 (8.3) at baseline, which 
improved to 4.4 (6.2) at 6 months, P = 0.60, and 4.2 
(6.2) at 1 year post-treatment, P = 0.050 (Table 4). At 
baseline, 10.3% had at least mild depression, with 8.0% at 
6 months, P = 0.60, and 7.1% at 1 year, P = 0.64. At 
baseline, 37.9, 41.4, and 58.6% of patients endorsed 
symptoms in the cognitive, affective, and somatic domains 
of the BDI-II, respectively. At 1 year post-treatment, there 
was a significant improvement in the mean affective 
domain score of BDI, from 1.3 (2.0) to 0.64 (1.1), P = 0.010, 
while there were no significant changes in cognitive and 
somatic domains. Stratified by treatment modality, there 
was no difference in BDI-II outcomes between the surgical 
and medically treated patients shown in Supplementary 
Table 4.
Amongst 21 patients treated with surgery, 14.3% had 
controlled BP at baseline which increased to 38.1% at 1 year 
post-surgery, while 85.7% had potassium ≥3.5 mmol/L at 
baseline, which increased to 95.2% at 12 months post-
surgery. Amongst 13 patients treated with medications, 
7.7% had controlled BP at baseline, which increased to 
30.8% at 12 months post-treatment, while 76.9% had 
potassium ≥ 3.5 mmol/L at baseline, which increased 
Figure 2
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to 84.6% at 12 months post-treatment. There were no 
significant differences in the proportion of patients with 
controlled blood pressure or potassium ≥ 3.5 mmol/L 
between the surgically and medically treated groups. 
There were no differences in HRQoL between patients with 
controlled BP or potassium, compared to those without 
controlled BP or potassium.
Discussion
In this prospective observational study, we found that 
treatment for PA improved HRQoL in a multi-ethnic Asian 
cohort from baseline to 1 year after treatment. There were 
improvements in both summative scores, PCS and MCS, as 
well as four of eight RAND-36 domains. To our knowledge, 
this is the first prospective HRQoL study done in an Asian 
population and adds to those previously conducted in 
Caucasian patients (5, 10, 11). In addition to the HRQoL 
assessment, we also found that 10% of our cohort with no 
history of psychiatric illness had at least mild depression 
using the BDI-II. Previous studies have demonstrated that 
patients with PA may have more symptoms of depression 
and anxiety (23). All of our patients had successful bilateral 
cannulation on AVS which allowed accurate subtyping 
of PA and appropriate surgery for unilateral disease. With 
this, we also found that surgery led to better outcomes in 
HRQoL compared with medications, adding to other data 
currently supporting the superiority of surgery in terms 
of cardiovascular and renal outcomes (2). Furthermore, 
male patients generally responded better with surgery 
compared to medical therapy, which is likely due to the 
anti-androgenic side effects of MR antagonists.
Patient-perceived health outcomes have an 
increasingly important role in healthcare. One of the 
most widely used questionnaires is the RAND-36, a 
generic HRQoL questionnaire which captures multiple 
aspects of health in eight domains. Summative scores for 
physical (PCS) and mental (MCS) can be obtained, but 
these are weighted differently for different populations. 
For example, role emotional is more closely related to MCS 
than PCS in Asians (24). Despite these differences, we found 
that treatment led to improvements in both summative 
scores in our Asian cohort, similar to previous studies in 
Australia (10, 11) and Europe (5). In addition to causing 
hypertension, aldosterone excess has direct deleterious 
effects on various organs, leading to an increased risk of 
cardiovascular and renal disease. It may have similar effects 
on the brain as MR receptors are abundant in the CNS 
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possibly due to resolution of the various manifestations 
of PA, such as improvement of hypertension, resolution 
of hypokalaemia (and muscle weakness) and nocturia. 
Interestingly, we did not find a poorer HRQoL at baseline 
in our cohort unlike previous studies (26). This could be 
due to differences in the perception of health and illness 
in Asian individuals from other ethnicities (27). We also 
found that some improvements were noted only after 1 
year post-treatment. This suggests that improvements in 
HRQoL may extend beyond the initial 3–6 months similar 
to other beneficial effects such as blood pressure of which 
improvement might not be observed immediately upon 
treatment (28).
We found that surgical treatment for PA led to better 
outcomes in HRQoL compared with medical therapy, 
with improvements seen in PCS and the mental health 
domain of RAND-36, and EQ-5D index score, in the 
surgical group but not in the medical group. Velema and 
colleagues similarly found that patients treated with 
surgery had better HRQoL compared to those treated with 
medications (5). In addition, the higher defined daily dose 
(DDD) of antihypertensive medications was related to 
poorer HRQoL in patients treated with MR antagonists. 
Although MR antagonists are particularly effective for 
correcting both hypokalaemia and hypertension in 
PA, these medications may also worsen HRQoL due to 
its various side effects. In addition, there might be an 
incomplete blockade of mineralocorticoid receptors when 
treated with MR antagonists (5). While adrenalectomy 
leads to normalisation of aldosterone levels, patients on 
MR antagonists have persistent hyperaldosteronism which 
may continue to exert harmful effects via non-MR mediated 
mechanisms (29, 30). In addition, there has been evidence 
of excess glucocorticoid in patients with both unilateral 
and bilateral PA (31), which will not be adequately rectified 
with MR antagonists (32).
Differences in outcomes between men and women 
have been observed in previous studies. Women may 
report poorer HRQoL outcomes compared with men both 
at baseline and after treatment (5, 33). While there were no 
differences at baseline, we found that women had greater 
improvement in HRQoL compared to men and also better 
post-treatment EQ-5D visual score compared to men. This 
was likely explained by the poorer HRQoL seen in men 
on MR antagonists. We found that 50% of men had issues 
while on MR antagonists, compared with none having 
issues after surgery. Three of six patients initially started 
on spironolactone had anti-androgenic side effects, which 
required them to change to eplerenone. Another four were 
initiated on eplerenone and did not have any issues. The 
higher pill burden may also have contributed to poorer 
QOL seen in the medically treated group, with higher use of 
antihypertensive medication (DDD) at 1 year, 2.0 (0–5.6), 
compared to the surgical group, 0.5 (0–2.5), P = 0.018, 
which was also observed in the earlier study by Velema (5). 
In another study by Yoshida and colleagues which assessed 
only patients treated with MR antagonists, they found 
improvements in HRQoL after medical therapy, and less 
marked improvement in females compared to male patients. 
The difference between our studies may be due to the choice 
of MR antagonists used. Most of our patients were treated 
with spironolactone (69.2%), compared with most patients 
in the study by Yoshida treated with eplerenone, which 
has less anti-androgenic side effects (26). Although MR 
antagonists may cause mastalgia or menstrual irregularities 
in women, due to its anti-androgenic effects, this is likely 
to be more distressing for men who may experience 
gynaecomastia and a decrease in libido. On the other hand, 
while MR antagonists may be better tolerated in women, 
surgical cure rates are higher in women who undergo 
adrenalectomy (34). Hence, there is a strong argument for 
pursuing subtype testing in both genders.
Table 4 Changes in BDI-II from baseline to 6 months and 1 year.
BDI-II Baseline (n = 29) 6 months (n =25) P* 1 year (n = 28) P+
BDI score 6.2 (8.3) (n = 28) 4.4 (6.2) 0.60 4.2 (6.2) 0.050
% with reported issue
 CAT 3 (10.7%) (n = 28) 2 (8.0%) 0.74 2 (7.1%) 0.64
 Cognitive 11 (37.9%) 7 (28.0%) 0.44 5 (17.9%) 0.092
 Affective 12 (41.4%) 8 (32.0%) 0.48 9 (32.1%) 0.47
 Somatic 17 (60.7%) (n = 28) 18 (72.0%) 0.39 20 (71.4%) 0.40
Cognitive 1.9 (3.8) 1.4 (3.0) 0.81 1.1 (3.1) 0.057
Affective 1.3 (2.0) 0.64 (1.1) 0.056 0.64 (1.1) 0.010
Somatic 2.9 (3.4) (n = 28) 2.3 (2.9) 0.83 2.5 (2.9) 0.40
Values are presented in mean (s.d.) or number (percentage) .
*Baseline vs 6 months; +Baseline vs 1 year.
CAT, categorical grouping of 0–13 (minimal depressive symptoms) vs 14–63 (some form of depressive symptoms)
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In addition to poorer HRQoL, patients with PA may 
have higher rates of depression and anxiety. Aldosterone 
has been shown to cause disturbances in psychological 
functions (35) and MR overactivity may play a role in 
depression, while MR antagonist may alleviate anxiety 
and depression (36). Depression is important to recognise 
as concomitant depression can lead to poor adherence to 
medications (37). While we have no population norms for 
comparison, our BDI-II mean score of 6.2 was generally 
low and comparable to cohorts of medical patients (38), 
with only 10.3% of patients classified with at least mild 
depressive symptoms. Somatic complaints were the most 
commonly endorsed symptom domain on the BDI-II with 
58.6% reporting somatic complaints, including loss of 
energy, sleep disturbances, poorer appetite and fatigue. It is 
important to note that somatic complaints are not specific 
to depression and may be an effect of chronic illness (39). 
Nevertheless, with the high prevalence of stigma towards 
mental illness in Asians, who are less forthcoming in 
seeking psychiatric help, it is useful to screen and identify 
potential cases of depression for more detailed evaluation 
by mental health professionals (40). We observed a small 
but significant improvement in affective symptoms at 1 
year post-treatment. This suggests that treatment of PA can 
improve patients’ moods. Finally, there was no significant 
difference in anxiety and depression between our treatment 
groups, which is in line with a previous study (41).
This is the first study in an Asian cohort demonstrating 
improvement in HRQoL and depressive symptoms after 
treatment. Our prospective design reduces the risk of recall 
bias, and significant improvements were seen in our cohort 
at 1 year post-treatment. We recognise several limitations in 
our study. First, we included mainly English-literate patients 
for assessment of HRQoL who may respond differently 
to non-English-literate patients. The patients included 
were expectedly younger with higher eGFR but otherwise 
were similar in baseline characteristics. Furthermore, 
we had a high rate of recruitment (93%), reducing the 
risk of healthy volunteer bias. Secondly, patients treated 
with surgery exclusively have unilateral PA, while most 
on medications have bilateral PA. Inherent differences 
between these groups may explain treatment differences. 
However, it is uncommon for patients with unilateral PA to 
be treated with medications, precluding this comparison. 
We previously compared treatment outcomes in only 
patients with unilateral PA and found better blood pressure 
outcomes with surgery (28). Thirdly, our cohort was 
relatively small and may have been underpowered to assess 
for differences between treatment groups. Nevertheless, 
we still found better outcomes with surgery than medical 
treatment, and our results are consistent with those in 
other cohorts. Finally, generic HRQoL questionnaires were 
used, and using disease-specific questionnaires may be 
better in identifying issues faced by patients with PA (e.g. 
nocturia), and also demonstrate greater improvements 
post-surgery. A recently developed PA-specific HRQoL 
questionnaire (42) may be usual in that regard and this will 
be an area worth studying in the future.
In conclusion, we found an improvement in HRQoL 
and depressive symptoms in patients with PA after surgical 
and medical treatment, with better outcomes observed 
after surgery. This underscores the importance of diagnosis 
of PA, accurate subtyping, and appropriate treatment to 
improve HRQoL and general well-being, in addition to 
other benefits of cardiovascular and renal outcomes.
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